Magnetic resonance spectroscopy performance for detection of dementia, Alzheimer's disease and mild cognitive impairment in a community-based survey
- PMID: 18566544
- DOI: 10.1159/000140624
Magnetic resonance spectroscopy performance for detection of dementia, Alzheimer's disease and mild cognitive impairment in a community-based survey
Abstract
Background/aims: To evaluate (1)H-labelled magnetic resonance spectroscopy (MRS) in patients with a low Mini Mental State Examination (MMSE) score identified during a dementia community-based survey.
Methods: A population sample of 1,500 individuals (>64 years old) was randomly selected. Two hundred and fifteen individuals (MMSE < or =24) were sorted into clinical groups: dementia, Alzheimer's disease, mild cognitive impairment (MCI), normal. Up to 56 of these individuals attended the MRS appointment. Two single-voxel sequences (TR 1,500, TE 35/144 ms) were carried out in the posterior cingulate gyrus of each individual, and the ratios N-acetylaspartate (NAA)/creatine (Cr), choline (Cho)/Cr, myo-inositol (mI)/Cr, NAA/mI and NAA/Cho were compared statistically. The ability of MRS to distinguish clinical groups was assessed by receiver-operating characteristics analysis. Cognition effects on metabolite ratios were estimated, with gender and cognition as categorical variables and age as a continuous covariate.
Results: NAA/Cr and NAA/Cho ratios were lower in dementia or Alzheimer's disease than in MCI and normal groups. The NAA/Cr ratio at TE 35 ms performed best when distinguishing dementia or Alzheimer's disease from non-demented subjects (cut-off point 1.40). MRS could not distinguish between MCI patients and normal subjects. Dementia was an independent predictor of metabolite values.
Conclusion: In a population sample, conventional MRS still proved to be a useful tool for dementia discrimination, but it is potentially far less useful as a surrogate marker for MCI.
Copyright 2008 S. Karger AG, Basel.
Similar articles
-
In vivo proton magnetic resonance spectroscopy of the temporal lobe in Alzheimer's disease.Prog Neuropsychopharmacol Biol Psychiatry. 2004 Dec;28(8):1313-22. doi: 10.1016/j.pnpbp.2004.08.013. Prog Neuropsychopharmacol Biol Psychiatry. 2004. PMID: 15588758
-
Regional metabolic changes in the hippocampus and posterior cingulate area detected with 3-Tesla magnetic resonance spectroscopy in patients with mild cognitive impairment and Alzheimer disease.Acta Radiol. 2009 Apr;50(3):312-9. doi: 10.1080/02841850802709219. Acta Radiol. 2009. PMID: 19235582
-
Proton spectroscopy in Alzheimer's disease and cognitive impairment no dementia: a community-based study.Dement Geriatr Cogn Disord. 2008;25(6):491-500. doi: 10.1159/000128275. Epub 2008 Apr 28. Dement Geriatr Cogn Disord. 2008. PMID: 18441524 Clinical Trial.
-
[Alzheimer's disease and magnetic resonance spectroscopy of the hippocampus].Arq Neuropsiquiatr. 2001 Dec;59(4):865-70. doi: 10.1590/s0004-282x2001000600006. Arq Neuropsiquiatr. 2001. PMID: 11733829 Review. Portuguese.
-
1H-MRS evaluation of metabolism in Alzheimer's disease and vascular dementia.Neurol Res. 2004 Jul;26(5):488-95. doi: 10.1179/016164104225017640. Neurol Res. 2004. PMID: 15265265 Review.
Cited by
-
[MR spectroscopy in dementia].Radiologe. 2010 Sep;50(9):791-8. doi: 10.1007/s00117-009-1947-3. Radiologe. 2010. PMID: 20552158 German.
-
Brain imaging of mild cognitive impairment and Alzheimer's disease.Neural Regen Res. 2013 Feb 15;8(5):435-44. doi: 10.3969/j.issn.1673-5374.2013.05.007. Neural Regen Res. 2013. PMID: 25206685 Free PMC article.
-
Various MRS application tools for Alzheimer disease and mild cognitive impairment.AJNR Am J Neuroradiol. 2014 Jun;35(6 Suppl):S4-11. doi: 10.3174/ajnr.A3944. Epub 2014 Apr 17. AJNR Am J Neuroradiol. 2014. PMID: 24742809 Free PMC article. Review.
-
Cerebral metabolic changes in neurologically presymptomatic patients undergoing haemodialysis: in vivo proton MR spectroscopic findings.Eur Radiol. 2010 Jun;20(6):1502-7. doi: 10.1007/s00330-009-1673-2. Epub 2009 Dec 8. Eur Radiol. 2010. PMID: 19997847
-
Mitochondrial dysfunction, oxidative stress, neuroinflammation, and metabolic alterations in the progression of Alzheimer's disease: A meta-analysis of in vivo magnetic resonance spectroscopy studies.Ageing Res Rev. 2021 Dec;72:101503. doi: 10.1016/j.arr.2021.101503. Epub 2021 Oct 29. Ageing Res Rev. 2021. PMID: 34751136 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical